1. MRRs and EMRRs for women with ACS
STEMI (N=60,712)
NSTEMI (N=119,656)
MRR (95% CI)
EMRR (95% CI)
Adjusted for age, year of hospitalization
6 months
1.01 ( )
2.12 ( )*
0.93 ( )*
1.14 ( )*
1 year
1.01 ( )
3.29 ( )*
0.93 ( )*
1.24 ( )*
5 year
1.03 ( )
1.91 ( )*
0.95 ( )*
1.35 ( )*
Adjusted for age, year of hospitalization, comorbidities
1.02 (0.98–1.06)
1.65 (1.50–1.81)*
0.96 (0.94–0.99)
1.15 (1.11–1.19)*
1.01 (0.96–1.05)
1.89 (1.66–2.16)
0.97 (0.95–0.99)
1.20 (1.16–1.24)*
1.03 (0.99–1.07)
1.60 (1.48–1.72)*
1.26 (1.21–1.32)*
Adjusted for age, year of hospitalization, comorbidities, treatments at discharge
0.94 (0.91–0.98)*
1.26 (1.16–1.37)*
0.88 (0.86–0.90)*
0.97 (0.94–1.00)
0.92 (0.89–0.96)*
1.43 (1.26–1.62)*
0.88 (0.87–0.90)*
1.01 (0.97–1.04)
0.93 (0.89–0.96)*
1.31 (1.19–1.43)*
0.89 (0.87–0.91)*
1.07 (1.02–1.12)*
*Significance level <0.05
ACS: acute coronary syndrome; STEMI: ST-segment-elevation myocardial infarction; NSTEMI: non-ST-segment-elevation myocardial infarction; MRR: mortality rate ratio; EMRR: excess mortality rate ratio; CI: confidence interval.
Comorbidities: DM, hypertension, MI, cerebrovascular diseases, peripheral vascular disease, HF
Treatments at discharge: Aspirin, b-blockers, statin, ACE inhibitors or ARBs, P2Y12 inhibitors, reperfusion (fibrinolysis or primary PCI), revascularization (PCI or CABG)
Alabas OA, et al. JAHA 2017;6:e007123